Podcast appearances and mentions of Richard S Finn

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry Introduction (0:00) Faculty Presentation (3:08) IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43) Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15) Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34) Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn  Faculty Presentation (31:18) EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15) Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29) Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05) Current First-Line Therapy for Advanced HCC — Dr He Faculty Presentation (1:00:39) Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00) Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22) Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03) Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein  Faculty Presentation (1:29:42) Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59) Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27) Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20) CME information and select publications

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics. Introduction (0:00) Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30) Biliary Tract Cancers (BTCs) — Dr Finn (33:16) CME information and select publications

Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, including the following topics: Introduction (0:00) Prologue: Last Week (2:33) Hepatocellular Carcinoma (4:37) Biliary Tract Cancers (35:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 2: Biliary Tract Cancers — Dr Richard S Finn CME information and select publications

Proceedings from our Year in Review webinar on colorectal cancer. Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, moderated by Dr Neil Love.

Proceedings from our Year in Review webinar on colorectal cancer. Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, moderated by Dr Neil Love.

Proceedings from our Year in Review webinar on colorectal cancer. Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, moderated by Dr Neil Love.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

Host: Robert Mocharnuk, MD Guest: Richard S. Finn, MD Guest: Amit Singal, MD, MS The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC. Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management. Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management ...

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don't miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients' needs.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes